

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ATAI Life Sciences B.V.</u> <hr/> (Last) (First) (Middle) <u>KRAUSENSTRASSE 9-10</u> <hr/> (Street) <u>BERLIN 2M</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/14/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>IntelGenx Technologies Corp. [ IGXT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.00001 par value per share	37,300,000	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrant (Right to Buy)	(1)	05/14/2024	Common Stock, \$0.00001 par value	22,380,000 <sup>(2)</sup>	0.35	D	
Warrant (Right to Buy)	(1)	05/14/2024	Common Stock, \$0.00001 par value	130,000,000 <sup>(3)</sup>	(3)	D	
Warrant (Right to Buy)	(1)	(4)	Common Stock, \$0.00001 par value	(4)	(4)	D	

1. Name and Address of Reporting Person* <u>ATAI Life Sciences B.V.</u> <hr/> (Last) (First) (Middle) <u>KRAUSENSTRASSE 9-10</u> <hr/> (Street) <u>BERLIN 2M</u> <hr/> (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>ATAI Life Sciences AG</u> <hr/> (Last) (First) (Middle) <u>KRAUSENSTRASSE 9-10</u> <hr/> (Street) <u>BERLIN 2M</u> <hr/> (City) (State) (Zip)
---

(City)

(State)

(Zip)

**Explanation of Responses:**

1. See Exhibit 99.1
2. See Exhibit 99.1
3. See Exhibit 99.1
4. See Exhibit 99.1

**Remarks:**

In April 2021, ATAI Life Sciences AG was acquired by ATAI Life Sciences B.V. as a consequence of a capital increase of ATAI Life Sciences B.V. in the context of which the shareholders of ATAI Life Sciences AG contributed and transferred their shares in ATAI Life Sciences AG as a contribution in kind to ATAI Life Sciences B.V., resulting in ATAI Life Sciences AG becoming a wholly-owned subsidiary of ATAI Life Sciences B.V. and the shareholders of ATAI Life Sciences AG becoming the shareholders of ATAI Life Sciences B.V. Accordingly, this Form 3 has been filed on behalf of ATAI Life Sciences AG and ATAI Life Sciences B.V.

/s/ Florian Brand, Chief  
Executive Officer of ATAI  
Life Sciences B.V. and  
ATAI Life Sciences AG

05/24/2021

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

Explanation of Responses:

(1) Immediately exercisable.

(2) On March 14, 2021, the Issuer entered into a securities purchase agreement (the "Initial Securities Purchase Agreement") with ATAI Life Sciences AG providing for the purchase of the Initial Units (as defined below) and the Additional Units Warrant (as defined below) by ATAI Life Sciences AG (the "Investment"). Under the Initial Securities Purchase Agreement, ATAI Life Sciences AG agreed to purchase, following receipt of approval of the stockholders of the Issuer (the "Stockholders") at the Issuer's Annual Meeting of the Stockholders (the "Meeting"), (A) an aggregate of 37,300,000 units of the Issuer (the "Initial Units") at a price of US\$0.331 per Initial Unit, each Initial Unit to be issued being comprised of one share of Common Stock (an "Initial Share") and 0.60 of a warrant (each whole warrant, an "Initial Warrant") for an aggregate consideration of US\$12,346,300, and (B) a warrant (the "Additional Units Warrant") to acquire up to 130,000,000 additional units of the Issuer (the "Additional Units" and collectively with the Initial Units, the "Units") for a period of three years from the closing of the initial investment, each Additional Unit to be issued being comprised of one share of Common Stock (an "Additional Warrant Share") and 0.50 of one warrant (each such whole warrant, an "Additional Warrant" and collectively with the Initial Warrants, the "Warrants").

On May 11, 2021, the Stockholders of the Issuer approved the Investment at the Meeting, and the Initial Securities Purchase Agreement was amended and restated on May 14, 2021 (together with the Initial Securities Purchase Agreement, the "Securities Purchase Agreement") in order to effect certain mechanical amendments involving settlement of securities.

(3) Under the Securities Purchase Agreement, ATAI Life Sciences AG is entitled, upon exercise of the Additional Units Warrant, to purchase up to 130,000,000 Additional Units at the following purchase price: (a) for Additional Units purchased on or before the first anniversary of the Meeting and that do not result in ATAI Life Sciences AG owning more than 74,600,000 shares of Common Stock, US\$0.331 per Additional Unit; or (b) for Additional Units purchased (x) that cause ATAI Life Sciences AG to hold more than 74,600,000 shares of Common Stock or (y) after the first anniversary of the Meeting, the lower of: (i) 120% of the subsequent closing volume weighted average trading price per Additional Unit; or (ii) before the second anniversary of the Meeting, US\$0.50 per Additional Unit and after the second anniversary of the Meeting, US\$0.75 per Additional Unit.

(4) Each Additional Warrant would entitle ATAI Life Sciences AG to purchase one Additional Warrant Share for a period of 36 months following their date of issuance, at an exercise price equal to the price per Additional Unit plus a premium of 20%; provided, that, the exercise of any Additional Warrants may not exceed the lesser of (x) 44,000,000 shares of Common Stock (subject to customary anti-dilution adjustments) and (y) the number of shares of Common Stock issued by the Issuer to persons other than ATAI Life Sciences AG and its affiliates having a right to convert existing convertibles, warrants and other instrument held by such persons as of February 15, 2021 (collectively, "Outstanding Convertibles"). The Additional Warrants will further provide that the exercise price for a given Additional Warrant may be, at ATAI Life Sciences AG's discretion, adjusted downward to equal the exercise price per share of Common Stock of any Outstanding Convertibles that were exercised and to which the exercise of the Additional Warrant Share is associated for the purposes of (x) above.